bluebird bio - BLUE Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $6.75
Forecasted Upside: 1.35%
Number of Analysts: 9
Breakdown:
2 Sell Ratings
6 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$6.66 As of 02/7/2023 01:57 PM ET

+0 (0.00%)

1 month | 3 months | 12 months

Get New bluebird bio Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BLUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLUE

^$6.75

▲ +1.35% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for bluebird bio in the last 3 months. The average price target is $6.75, with a high forecast of $10.00 and a low forecast of $3.00. The average price target represents a 1.35% upside from the last price of $6.66.

Current Consensus is Hold

The current consensus among 9 polled investment analysts is to hold stock in bluebird bio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
14 hold ratings
2 sell ratings

Ratings as of

8/16/2021

0 strong buy ratings
2 buy ratings
14 hold ratings
2 sell ratings

Ratings as of

11/14/2021

0 strong buy ratings
2 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

2/12/2022

0 strong buy ratings
1 buy ratings
12 hold ratings
2 sell ratings

Ratings as of

5/13/2022

0 strong buy ratings
2 buy ratings
8 hold ratings
2 sell ratings

Ratings as of

8/11/2022

0 strong buy ratings
1 buy ratings
8 hold ratings
2 sell ratings

Ratings as of

11/9/2022

0 strong buy ratings
1 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

1/8/2023

0 strong buy ratings
1 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

2/7/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/24/2023	Morgan Stanley	Boost Target	Underweight	$3.00 ➝ $4.00	Low
1/23/2023	SVB Leerink	Lower Target	Market Perform	$9.00 ➝ $8.00	Low
1/6/2023	SVB Leerink	Boost Target	Market Perform	$8.00 ➝ $9.00	Low
11/8/2022	Royal Bank of Canada	Lower Target	Sector Perform	$8.00	Low
9/20/2022	Raymond James	Boost Target	Outperform	$8.00 ➝ $10.00	Low
8/19/2022	The Goldman Sachs Group	Boost Target	Sell	$2.00 ➝ $3.00	Low
8/18/2022	SVB Leerink	Boost Target	Market Perform	$8.00 ➝ $10.00	Low
8/5/2022	Barclays	Upgrade	Underweight ➝ Equal Weight	$3.00 ➝ $5.00	Low
8/2/2022	Raymond James	Upgrade	Market Perform ➝ Outperform	$8.00	Low
5/17/2022	Morgan Stanley	Lower Target	Underweight	$3.00	Medium
5/10/2022	Wedbush	Lower Target	Neutral	$10.00 ➝ $8.00	High
5/10/2022	Barclays	Lower Target		$4.00 ➝ $3.00	High
4/6/2022	SVB Leerink	Lower Target	Market Perform	$10.00 ➝ $8.00	Medium
4/6/2022	Cowen	Downgrade	Outperform ➝ Market Perform		Medium
3/8/2022	Wells Fargo & Company	Lower Target	Equal Weight	$12.00 ➝ $8.00	High
3/7/2022	Morgan Stanley	Lower Target	Underweight	$6.00 ➝ $5.00	Medium
3/7/2022	SVB Leerink	Lower Target	Market Perform	$11.00 ➝ $10.00	Low
3/7/2022	Barclays	Downgrade	Equal Weight ➝ Underweight	$13.00 ➝ $4.00	Low
1/6/2022	Morgan Stanley	Lower Target	Underweight	$11.00 ➝ $10.00	Medium
1/3/2022	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		Low
12/23/2021	SVB Leerink	Reiterated Rating	Hold		Low
11/12/2021	Berenberg Bank	Reiterated Rating	Hold	$11.00	Medium
11/12/2021	BMO Capital Markets	Lower Target	Market Perform	$21.00 ➝ $13.00	Low
11/8/2021	Wedbush	Lower Target	Neutral	$22.00 ➝ $11.00	High
11/8/2021	Royal Bank of Canada	Lower Target	Neutral ➝ Sector Perform	$26.00 ➝ $14.00	High
11/8/2021	Wells Fargo & Company	Lower Target	Equal Weight	$25.00 ➝ $16.00	High
11/8/2021	Barclays	Lower Target	Equal Weight	$20.00 ➝ $13.00	High
11/8/2021	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$23.00 ➝ $10.00	High
11/8/2021	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$11.00	High
9/22/2021	Mizuho	Lower Target	Buy	$29.00 ➝ $23.00	High
8/10/2021	William Blair	Initiated Coverage	Market Perform		Medium
8/10/2021	BMO Capital Markets	Lower Target	Market Perform	$29.00 ➝ $21.00	High
8/10/2021	Bank of America	Lower Target	Neutral	$41.00 ➝ $22.00	High
8/10/2021	Mizuho	Lower Target	Buy	$70.00 ➝ $29.00	High
8/10/2021	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$63.00 ➝ $23.00	High
8/10/2021	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$60.00 ➝ $25.00	High
8/9/2021	Stifel Nicolaus	Lower Target	Hold	$31.00 ➝ $18.00	High
8/9/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$64.00 ➝ $20.00	High
8/1/2021	SVB Leerink	Reiterated Rating	Buy		Low
7/16/2021	Morgan Stanley	Lower Target	Equal Weight	$36.00 ➝ $35.00	High
7/1/2021	Berenberg Bank	Downgrade	Buy ➝ Hold	$35.00	Low
6/15/2021	Oppenheimer	Reiterated Rating	Hold		Medium
6/10/2021	SVB Leerink	Initiated Coverage	Buy		Medium
4/21/2021	BMO Capital Markets	Lower Target	Market Perform	$35.00 ➝ $31.00	Medium
4/19/2021	Morgan Stanley	Lower Target	Equal Weight	$45.00 ➝ $36.00	Medium
3/29/2021	Piper Sandler	Boost Target		$30.00 ➝ $35.00	High
3/29/2021	Jefferies Financial Group	Reiterated Rating	Buy		High
3/29/2021	SVB Leerink	Boost Target	Outperform	$69.00 ➝ $72.00	N/A
3/29/2021	BMO Capital Markets	Boost Target	Market Perform	$31.00 ➝ $35.00	High
3/28/2021	Oppenheimer	Reiterated Rating	Hold		High
3/14/2021	SVB Leerink	Reiterated Rating	Buy		Medium
3/10/2021	Stifel Nicolaus	Boost Target		$26.00 ➝ $31.00	Medium
3/10/2021	Mizuho	Upgrade	Neutral ➝ Buy	$34.00 ➝ $69.00	High
3/2/2021	Morgan Stanley	Lower Target	Equal Weight	$50.00 ➝ $45.00	Medium
2/24/2021	Barclays	Lower Target	Equal Weight	$31.00 ➝ $27.00	Medium
2/17/2021	BMO Capital Markets	Boost Target	Market Perform	$36.00 ➝ $56.00	Low
2/17/2021	Stifel Nicolaus	Lower Target	Hold	$48.00 ➝ $35.00	Low
2/17/2021	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform		Low
2/17/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$76.00 ➝ $39.00	Low
2/16/2021	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
2/16/2021	Bank of America	Downgrade	Buy ➝ Neutral		Low
2/16/2021	Wedbush	Downgrade	Outperform ➝ Neutral		Low
2/16/2021	Mizuho	Downgrade	Buy ➝ Neutral		Low
2/16/2021	Piper Sandler	Lower Target	Neutral	$55.00 ➝ $35.00	Low
2/16/2021	William Blair	Downgrade	Outperform ➝ Market Perform		Low
12/9/2020	Maxim Group	Downgrade	Buy ➝ Hold		High
12/7/2020	Mizuho	Reiterated Rating	Buy		High
11/11/2020	Berenberg Bank	Initiated Coverage	Buy	$64.00	Low
11/11/2020	Morgan Stanley	Lower Target	Equal Weight	$68.00 ➝ $50.00	Low
11/6/2020	Wedbush	Lower Target	Outperform	$81.00 ➝ $73.00	Medium
11/5/2020	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$77.00 ➝ $51.00	Medium
11/5/2020	Barclays	Downgrade	Overweight ➝ Equal Weight		High
11/5/2020	JPMorgan Chase & Co.	Lower Target	Overweight	$140.00 ➝ $76.00	High
11/5/2020	Wells Fargo & Company	Lower Target	Overweight	$94.00 ➝ $81.00	High
11/5/2020	SVB Leerink	Lower Target	Outperform	$133.00 ➝ $99.00	High
11/5/2020	Bank of America	Lower Target	Buy	$100.00 ➝ $81.00	High
11/5/2020	Royal Bank of Canada	Lower Target	Outperform	$100.00 ➝ $93.00	High
11/5/2020	Oppenheimer	Lower Target	Outperform	$111.00 ➝ $90.00	High
11/5/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$108.00 ➝ $56.00	High
11/4/2020	Piper Sandler	Lower Target	Neutral	$70.00 ➝ $55.00	High
11/2/2020	William Blair	Upgrade	Market Perform ➝ Outperform		Medium
10/19/2020	Mizuho	Initiated Coverage	Buy	$123.00	Medium
8/31/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	High
8/30/2020	William Blair	Reiterated Rating	Hold		High
8/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
8/10/2020	Morgan Stanley	Lower Target	Equal Weight	$73.00 ➝ $68.00	Medium
8/6/2020	BMO Capital Markets	Lower Target	Outperform	$112.00 ➝ $108.00	High
8/6/2020	Wedbush	Lower Target	Outperform	$89.00 ➝ $81.00	Medium
7/29/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	High
7/13/2020	Bank of America	Lower Target	Buy	$104.00 ➝ $100.00	High
6/12/2020	SVB Leerink	Boost Target	Outperform	$129.00 ➝ $133.00	Medium
6/1/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	Low
5/28/2020	Morgan Stanley	Boost Target	Equal Weight	$69.00 ➝ $73.00	Medium
5/28/2020	SVB Leerink	Boost Target	Outperform	$125.00 ➝ $129.00	Low
5/17/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	Medium
5/13/2020	Barclays	Reiterated Rating	Buy		High
5/12/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$100.00	High
5/12/2020	BMO Capital Markets	Boost Target	Outperform	$107.00 ➝ $112.00	High
5/11/2020	Oppenheimer	Initiated Coverage	Buy	$122.00 ➝ $111.00	High
5/11/2020	Piper Sandler	Lower Target	Neutral	$75.00 ➝ $70.00	High
4/15/2020	Morgan Stanley	Lower Target	Equal Weight	$92.00 ➝ $69.00	Low
3/27/2020	BMO Capital Markets	Lower Target	Outperform	$132.00 ➝ $107.00	Low
3/27/2020	William Blair	Reiterated Rating	Hold		Medium
3/26/2020	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$94.00 ➝ $70.00	Low
3/26/2020	Piper Sandler	Lower Target		$85.00 ➝ $75.00	Low
3/26/2020	Wells Fargo & Company	Reiterated Rating	Buy		Medium
2/26/2020	Morgan Stanley	Lower Target	Equal Weight	$100.00 ➝ $92.00	Low
2/20/2020	Oppenheimer	Lower Target		$135.00 ➝ $128.00	Low
2/19/2020	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		High
2/19/2020	Stifel Nicolaus	Lower Target	Hold	$96.00 ➝ $94.00	High
2/3/2020	Bank of America	Initiated Coverage	Buy	$120.00	High
2/3/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$86.00 ➝ $100.00	High
1/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
12/12/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$135.00	High
12/10/2019	William Blair	Reiterated Rating	Hold		High
12/9/2019	Wells Fargo & Company	Lower Target	Overweight	$242.00 ➝ $160.00	High
12/6/2019	Cowen	Reiterated Rating	Buy		Low
11/27/2019	Evercore ISI	Downgrade	Outperform ➝ In-Line		Medium
11/26/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$119.00	Low
11/21/2019	Cowen	Reiterated Rating	Buy		Medium
11/4/2019	Wedbush	Upgrade	Neutral ➝ Outperform	$131.00 ➝ $124.00	High
11/1/2019	Stifel Nicolaus	Set Target	Hold	$96.00	Low
11/1/2019	Morgan Stanley	Set Target	Hold	$104.00 ➝ $100.00	Low
11/1/2019	Maxim Group	Reiterated Rating	Buy	$130.00	Low
10/11/2019	Morgan Stanley	Lower Target	Equal Weight	$136.00 ➝ $104.00	Medium
10/9/2019	Stifel Nicolaus	Reiterated Rating	Hold		N/A
9/30/2019	Stifel Nicolaus	Initiated Coverage	Hold	$109.00	High
9/18/2019	William Blair	Reiterated Rating	Hold		Low
8/12/2019	William Blair	Downgrade	Outperform ➝ Market Perform		High
8/6/2019	Morgan Stanley	Lower Target	Equal Weight	$143.00 ➝ $136.00	Medium
7/19/2019	Gabelli	Reiterated Rating	Buy		N/A
6/18/2019	Maxim Group	Upgrade	Hold ➝ Buy	$160.00	High
6/17/2019	BMO Capital Markets	Lower Target	Outperform	$191.00 ➝ $163.00	Low
6/14/2019	Piper Jaffray Companies	Set Target	Hold	$120.00	Low
6/13/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$195.00	High
5/17/2019	JPMorgan Chase & Co.	Set Target	Buy	$195.00	Medium
5/16/2019	SunTrust Banks	Lower Target	Buy	$174.00	Medium
5/15/2019	Wedbush	Downgrade	Outperform ➝ Neutral	$166.00 ➝ $131.00	Medium
5/3/2019	BMO Capital Markets	Set Target	Buy	$191.00	High
5/3/2019	William Blair	Reiterated Rating	Buy		Medium
4/23/2019	William Blair	Reiterated Rating	Outperform		Low
3/22/2019	Cantor Fitzgerald	Set Target	Hold	$122.00	Low
3/5/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low
2/26/2019	Cowen	Initiated Coverage	Outperform	$149.91	High
2/25/2019	SunTrust Banks	Lower Target	Buy	$184.00	High
2/22/2019	BMO Capital Markets	Boost Target	Outperform	$194.00	Medium
2/22/2019	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$134.00 ➝ $122.00	Medium
1/11/2019	Oppenheimer	Reiterated Rating	Hold		Low
1/10/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
12/19/2018	Raymond James	Initiated Coverage	Strong-Buy ➝ Strong-Buy	$165.00	High
12/9/2018	Cowen	Reiterated Rating	Buy		Low
12/6/2018	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$240.00 ➝ $120.00	Medium
12/4/2018	Oppenheimer	Reiterated Rating	Hold		Low
12/4/2018	William Blair	Reiterated Rating	Buy		Low
12/3/2018	Janney Montgomery Scott	Set Target	Outperform ➝ Buy	$170.00	High
12/3/2018	Maxim Group	Reiterated Rating	Hold		High
12/3/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$134.00	High
11/27/2018	Oppenheimer	Reiterated Rating	Hold		High
11/27/2018	SVB Leerink	Initiated Coverage	Outperform	$145.00 ➝ $145.00	Low
11/14/2018	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$155.00	High
11/5/2018	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$186.00 ➝ $185.00	Low
11/5/2018	Wedbush	Lower Target	Outperform ➝ Outperform	$204.00 ➝ $166.00	Medium
11/5/2018	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$170.00 ➝ $170.00	Medium
11/4/2018	Piper Jaffray Companies	Reiterated Rating	Buy		Medium
11/2/2018	Cowen	Reiterated Rating	Buy		Medium
11/2/2018	Oppenheimer	Reiterated Rating	Hold		Low
11/2/2018	Cantor Fitzgerald	Upgrade	Underweight ➝ Neutral	$122.00 ➝ $134.00	Medium
11/1/2018	Maxim Group	Reiterated Rating	Hold		Medium
11/1/2018	William Blair	Reiterated Rating	Buy		High
10/15/2018	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$190.00 ➝ $186.00	Low
9/21/2018	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		Medium
9/17/2018	Guggenheim	Initiated Coverage	Neutral		Medium
9/5/2018	Cantor Fitzgerald	Set Target	Sell	$122.00	Low
9/5/2018	William Blair	Reiterated Rating	Buy		Medium
8/23/2018	Cantor Fitzgerald	Set Target	Sell	$122.00	Low
8/6/2018	Maxim Group	Reiterated Rating	Hold		Low
8/6/2018	Cowen	Reiterated Rating	Buy		Low
8/6/2018	Cantor Fitzgerald	Set Target	Sell	$122.00	Medium
8/3/2018	SunTrust Banks	Reiterated Rating	Buy	$223.00	High
8/3/2018	BMO Capital Markets	Reiterated Rating	Buy	$208.00	High
8/2/2018	Piper Jaffray Companies	Reiterated Rating	Buy		Medium
7/30/2018	Maxim Group	Lower Target	Hold	$163.00	Low
7/13/2018	Cantor Fitzgerald	Set Target	Sell	$122.00	Medium
7/12/2018	Gabelli	Initiated Coverage	Buy	$239.00	Low
6/19/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform	$175.00 ➝ $230.00	Low
6/5/2018	Piper Jaffray Companies	Set Target	Buy	$240.00	Low
6/4/2018	Cantor Fitzgerald	Upgrade	Underweight ➝ Overweight		Low
6/4/2018	Cowen	Reiterated Rating	Buy		High
6/3/2018	Cantor Fitzgerald	Set Target	Sell	$122.00	High
5/30/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Buy	$240.00	High
5/16/2018	Cantor Fitzgerald	Reiterated Rating	Underweight		Low
5/10/2018	Cantor Fitzgerald	Reiterated Rating	Sell	$122.00	Medium
5/7/2018	Sanford C. Bernstein	Reiterated Rating	Market Perform	$211.00	Low
5/3/2018	Maxim Group	Set Target	Hold	$200.00	High
5/3/2018	BMO Capital Markets	Lower Target	Outperform ➝ Buy	$222.00 ➝ $216.00	High
5/3/2018	BTIG Research	Reiterated Rating	Buy		High
4/19/2018	SunTrust Banks	Boost Target	Buy	$232.00	High
3/21/2018	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$152.00 ➝ $209.00	High
3/16/2018	William Blair	Reiterated Rating	Buy		Medium
3/16/2018	UBS Group	Initiated Coverage	Sell		High
3/14/2018	Janney Montgomery Scott	Initiated Coverage	Neutral ➝ Neutral	$220.00	Medium
3/8/2018	BTIG Research	Boost Target	Buy	$250.00	Medium
3/5/2018	William Blair	Initiated Coverage	Outperform ➝ Outperform	$206.10 ➝ $242.00	High
2/26/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$151.00 ➝ $152.00	Medium
2/22/2018	Maxim Group	Reiterated Rating	Hold	$200.00	Medium
2/22/2018	Bank of America	Boost Target	Neutral ➝ Neutral	$185.00 ➝ $218.00	Medium
2/22/2018	BMO Capital Markets	Set Target	Outperform ➝ Buy	$215.00 ➝ $222.00	High
2/22/2018	Sanford C. Bernstein	Reiterated Rating	Hold	$153.00 ➝ $211.00	High
2/22/2018	Cantor Fitzgerald	Lower Target	Underweight	$122.00 ➝ $113.00	High
2/21/2018	Cantor Fitzgerald	Reiterated Rating	Underweight ➝ Sell	$122.00 ➝ $113.00	High

(Data available from 2/7/2018 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

7 very positive mentions
5 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

7/12/2022

3 very positive mentions
4 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

8/11/2022

8 very positive mentions
16 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

9/10/2022

7 very positive mentions
13 positive mentions
5 negative mentions
0 very negative mentions

Mentions as of

10/10/2022

5 very positive mentions
7 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/9/2022

7 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/9/2022

3 very positive mentions
18 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

1/8/2023

7 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/7/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Today's Range

Now: $6.66

$6.56

$6.74

50 Day Range

MA: $7.25

$5.92

$8.49

52 Week Range

Now: $6.66

$2.87

$8.58

Volume

806,341 shs

Average Volume

4,058,518 shs

Market Capitalization

$552.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?: The following Wall Street sell-side analysts have issued stock ratings on bluebird bio in the last twelve months: Barclays PLC, Cowen Inc, Morgan Stanley, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for BLUE.
What is the current price target for bluebird bio?: 8 Wall Street analysts have set twelve-month price targets for bluebird bio in the last year. Their average twelve-month price target is $6.75, suggesting a possible upside of 1.4%. Raymond James has the highest price target set, predicting BLUE will reach $10.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $3.00 for bluebird bio in the next year.
View the latest price targets for BLUE.
What is the current consensus analyst rating for bluebird bio?: bluebird bio currently has 2 sell ratings, 6 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BLUE, but not buy more shares or sell existing shares.
View the latest ratings for BLUE.
What other companies compete with bluebird bio?: Other companies that are similar to bluebird bio include Mesoblast, NanoString Technologies, Cullinan Oncology, Compass Therapeutics and AlloVir. Learn More about companies similar to bluebird bio.
How do I contact bluebird bio's investor relations team?: bluebird bio's physical mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (339) 499-9300 and its investor relations email address is [email protected] The official website for bluebird bio is www.bluebirdbio.com. Learn More about contacing bluebird bio investor relations.

bluebird bio - BLUE Stock Price Target and Predictions

Analyst Price Target for BLUE

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.73 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

What is the current price target for bluebird bio?

What is the current consensus analyst rating for bluebird bio?

What other companies compete with bluebird bio?

How do I contact bluebird bio's investor relations team?